

October 24, 2017

Sarah Forster Materials Licensing Branch US Nuclear Regulatory Agency – Region III 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

RE: Materials License 21-08317-01, Munson Medical Center

Dear Ms. Forster,

This letter is to clarify information previously presented.

I request Dr. Forster be an Authorized User for all administration activities for 35.300 (below and above 33 mCi).

Please see included letter from University of Cincinnati verifying preceptors were Authorized Users at the time of Dr. Forster's training.

Also included is the Close Out Survey from Traverse Heart and Vascular.

Sincerely,

Dennis J. Aurand Dennis Aurand, MS, DABR®

Dennis Aurand, MS, DABR[®] Diagnostic Medical Physicist Radiation Safety Officer daurand@mhc.net phone: 231.392.8612 fax: 231.935.3204



College of Medicine Radiation Oncology The Barrett Center for Cancer Prevention, Treatment and Research University of Cincinnati Academic Health Center PO Box 670757 Cincinnati OH 45267-0757

234 Goodman Street Phone (513) 584-5668 Fax (513) 584-4007

October 24, 2017

Dennis Aurand, MS, DABR Radiation Safety Officer Diagnostic Medical Physicist Munson Medical Center Traverse City, MI

This memo confirms that the following preceptors for Neil Forster were Authorized Users on the UC Health Broad Scope license during his residency at University of Cincinnati Medical Center:

35.300 Unsealed Sources

Jennifer Scheler, MD (Uptake, dilution and excretion studies; imaging and localization; therapeutic administration) Mariano Fernandez-Ulloa, MD (Uptake, dilution and excretion studies; imaging and localization; therapeutic administration, other uses (Y90))

35.1000 (Y-90) Ross Ristagno, MD (Other uses, (Y90))

35.400, 35.600 Jordan Kharofa, MD (Linac, manual brachytherapy, remote afterloader brachytherapy).

If we can be of further assistance, please don't hesitate to contact us.

Michael Lamba, PhD

Michael Lamba, Ph.D. Director, Graduate Studies Department of Radiation Oncology College of Medicine University of Cincinnati Cincinnati, OH 45267 513-584-9028 michael.lamba@uc.edu

Date performed: September 14, 2017

Performed by: Dave Ingraham, CNMT

Comments: Sealed sources and radioactive trash were removed from these areas prior to survey and wipe testing.

Instruments

Wipe tests analyzed with a Captinec Caprac Well Counter #002120

Instrument: Well Counter

Radionuclide:	<u>Cs-137</u>	MDA for Cs-137	<u>689 dpm's</u>
Date completed:	<u>08/23/15</u>	Conversion factor:	10.32 dpm/dpm

Area survey performed with the following survey meter:

Manufacturer:	Ludlum
Туре:	GM
Model Number:	14C
Serial Number:	102699
Probe Model:	End Window
Annual Calibration D	ue: <u>12/22/17</u>

Battery check acceptable:YESOperational check acceptable:N/AConstancy check acceptable:YESCurrent reading:0.9 mR/hr

Radionuclides Used

Unsealed Tc99m, TI-201

Sealed

Ba-133, Cs-137, Co-57

Last date of byproduct radiopharmaceutical use:

September 11, 2017

Visual Check: The area was checked to ensure that all sealed sources and radioactive waste had been removed. No evidence of radioactive material was noted.

Sealed Source Leak Testing: Sealed Source Leak tests demonstrated no removable contamination.

Leaking Sources: There is no history of leaking sources at this facility.

Radiation Level Survey: No area within the department demonstrated radiation levels in excess of the background reading of 0.02 mR/hr.


Removable Contamination: *N*o area within the department demonstrated removable contamination excess of 50 dpm's.

Hot Lab, Imaging Area and Stress Rooms

Background: 462 cpm's

Area	Result in dpms
#1 Dose Prep	0
#2 Waste Storage	4
#3 Package Receipt	2
#4 Hot Lab Floor	50
#5 Exam Room	0
#6 Exam Room	8
#7 Camera	0
#8 Acq/Processing Area	0
#9 Camera	0
#10 Acq/Processing Are	a 0
#11 Treadmill	40
#12 Treadmill	0
#13 Acq/Processing Are	a 10
#14 Hallway	0
#15 Treadmill Floor	0
#16 Treadmill Floor	0
#17 Exam Room	0
#18 Hot Lab Floor	0
#19 Hot Lab	2
#20 Imaging Room Floo	r 0
#21 Processing Room F	loor 2
#22 Imaging Room Floo	r O

Maximum removable contamination = 50 dpms



Song, Taehoon

From:	Forster, Sara
Sent:	Tuesday, November 14, 2017 6:37 AM
То:	Song, Taehoon; Pavon, Sandy; Sandrik, Lauren
Subject:	FW: Additional Information for Munson Medical Center Amendment, Lic. 21-08317-01, CN600842
Attachments:	NRC THV decommissioning and Forster MD update October 24 2017.pdf; Forster NRC Preceptor Verifications.pdf; Traverse Heart and Vascular Close-Out 9-17 survey + map.pdf

Please scan in and return to me. Thank you!

Sara x9892

From: Aurand, Dennis [mailto:daurand@mhc.net] Sent: Monday, November 13, 2017 2:25 PM To: Forster, Sara <Sara.Forster@nrc.gov> Subject: [External_Sender] Update

I responded October 24, 2017. See below and attached.

Dennis Aurand

(231)392-8612

From: Forster, Sara [mailto:Sara.Forster@nrc.gov]
Sent: Monday, November 13, 2017 3:20 PM
To: Aurand, Dennis <<u>daurand@mhc.net</u>>
Subject: Additional Information Request re Munson Medical Center Amendment, Lic. 21-08317-01, CN600842

Dear Mr. Aurand:

On October 20, 2017, we discussed additional information needed to add Neil Forster, M.D., as an Authorized User (AU) on the above-referenced license. We were expecting a response within 14 days of the call (i.e. by 11/3/2017). Please let us know the status of your response. As discussed, a signed and dated letter, transmitting the requested information and attached to an email, would be fine.

As a reminder, please indicate the following in your response:

- 1. Regarding the requested 10 CFR 35.300 authorization for Dr. Forster, please confirm that you are requesting all oral and parenteral authorizations.
- Regarding training and preceptor AUs from the University of Cincinnati Medical Center (UCMC), please provide a copy of each applicable permit or a letter from the UCMC Radiation Safety Officer (RSO) confirming that:
 - Jennifer Scheler, M.D., has been approved as an AU (for 10 CFR 35.300 materials including oral sodium iodide I-131 and parenteral administrations) from – at a minimum – July 1, 2013 through July 10, 2017.

- Mariano Fernandez Ulloa, M.D., has been approved as an AU (for 10 CFR 35.300 materials including oral sodium iodide I-131 and parenteral administrations) from November 26, 2013 through June 26, 2015.
- Ross Ristagno, M.D., has been approved as an AU for oral sodium iodide I-131 administrations permitted under 10 CFR 35.300 from November 14-16, 2014.
- Jordan Kharofa, M.D., has been approved as an AU for 10 CFR 35.400 and 10 CFR 35.600 (limited to HDR) material from July 1, 2013 through June 30, 2017.
- 3. Regarding sealed sources transferred from the Suite to be removed from the license, please confirm that those sources were transferred to another area of use listed on the above referenced license.
- Regarding closeout surveys for the Suite to be removed from the license, please provide a copy of the final area survey results, including a diagram of the area surveyed with wipe locations keyed to spots noted on the diagram.

If you have any questions regarding this request, please let me know by phone or by email.

Sincerely,

Sara A. Forster, Health Physicist Licensing Reviewer U.S. Nuclear Regulatory Commission - Region III Division of Nuclear Materials Safety 2443 Warrenville Rd. - Ste. 210 Lisle, IL 60532-4352 <u>sara.forster@nrc.gov</u> Direct: (630) 829-9892 Facsimile: (630) 515-1078



Dennís Aurand (231)392-8612

From: Aurand, Dennis Sent: Tuesday, October 24, 2017 3:19 PM To: 'sarah.forster@nrc.gov' <<u>sarah.forster@nrc.gov</u>> Subject: Update

Please see attached.

Dennis Aurand, MS, DABR[®] Radiation Safety Officer Diagnostic Medical Physicist Munson Medical Center Traverse City, MI Ph 231-392-8612 daurand@mhc.net With MUNSON MEDICAL CENTER Mension NEADECARE Website | Maps

PLEASE NOTE: The information contained in this electronic mail message may be legally privileged, confidential and intended only for certain recipients. If you are not an intended recipient, you are hereby notified that any disclosure, reproduction, distribution or other use of this communication and any attachments is strictly prohibited. If you have received this communication in error, please notify the sender by reply transmission and delete the message without copying or disclosing it.